drugset / Trial / NCT00729053
Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
* Multi-Center * Randomized * Open-Label Study of single agent IMO-2055 * Patients who have Metastatic or Locally Recurrent Clear Cell Renal Carcinoma (RCC)
Timeline
- Start
- 2004-06
- Primary completion
- 2008-04
- Completion
- 2008-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | EMD 1201081 | Oligonucleotide (other) | 0.16 mg/kg | Subcutaneous |
| Comparator | EMD 1201081 | Oligonucleotide (other) | 0.64 mg/kg | Subcutaneous |